Acellular artificial antigen ... signal 2') and cytokine release ('signal 3'). Nanoengineering Approaches for Next-generation aAPCs Most current-generation aAPCs employ static isotropic ...

The density of tumor antigen in conjunction with major histocompatibility complex (MHC) class I molecules on the cell surface ... the middle of the signal peptide; and (3) pCOC-IL-2, expressing ...

is exposed for specific recognition by the T cell receptor (TCR) 3,4. The pathways for CD1 trafficking and glycolipid antigen presentation remain to be determined. Several reports have suggested ...

The binding of a T cell to its specified antigen on an MHC, a process known as “signal 1”, primes an immune response against all foreign cells containing that antigen. Additional immune molecules ...

coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) signaling domains. A low dose (approximately 1.5×10 ...

Tumor antigens are captured and displayed by antigen processing and presentation machinery (APM) on the cell surface by HLA ... SCCs show a 49.3% objective response rate to PD-1 therapy, while ...

The tumor microenvironment, tumor immunogenicity, antigen presentation ... cell receptor recognition of corresponding antigens on major histocompatibility complexes (MHCs) expressed by ...

High response rates have been reported with the use of T cells modified by chimeric antigen receptor ... the expected rate of 3-year event-free survival after autologous stem-cell transplantation ...

98% (48/49) demonstrated a T cell response to either antigen following vaccination ... 6 of 15 patients in the GEO-CM04S1 arm achieved ≥3-fold increases in Spike or Nucleocapsid-specific ...